| Date | Title | Description |
| 13.12.2024 | Angitia Biopharmaceuticals: $120 Million (Series C) Raised To Develop Therapeutics For Serious Musculoskeletal Diseases | Angitia Biopharmaceuticals – a clinical-stage biotechnology company focused on discovering and developing innovative therapeutics for serious musculoskeletal diseases – announced the closing of a $120 million Series C financing round. Bain ... |
| 12.08.2022 | Bolt throws a wrench in the pipeline, looking to conserve cash | A meltdown in the biotech market is making most execs cautious, including Bolt Biotherapeutics’ CEO, as the company hits the brakes on one preclinical asset and pauses other early-stage work to extend cash reserves by ... |
| 12.08.2022 | House passes historic drug pricing reforms, lining up decades-in-the-making win for Biden and Democrats | In 2019, Aptinyx’s stock cratered after it reported that its lead candidate failed a diabetic nerve pain trial. After some ‘further analysis,’ the biotech re-upped with that same non-opioid pain drug in two more mid-stage studies — another ... |
| 10.11.2021 | Aptinyx Reports Third Quarter 2021 Financial Results and Recent Highlights - Form 8-K | Aptinyx Reports Third Quarter 2021 Financial Results and Recent Highlights
Completed enrollment in Phase 2b study of NYX-2925 in patients with painful diabetic peripheral neuropathy; results expected in early to mid 2Q 2022
Phase 2b fibromy... |
| 16.09.2021 | Aptinyx : Secures $50 Million Growth Capital Credit Facility from K2 HealthVentures | Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has entered into a $50 million loan facility and se... |
| 10.08.2021 | Aptinyx : Initiating CEO transition plan—effective January 1, 2022, Aptinyx CEO Norbert Riedel will assume role of executive chairperson and be succeeded by president and COO, Andy Kidd (Form 8-K) | Initiating CEO transition plan-effective January 1, 2022, Aptinyx CEO Norbert Riedel will assume role of executive
chairperson and be succeeded by president and COO, Andy Kidd
Conference call today at 5:00 p.m. ET
EVANSTON, Ill., August 10,... |
| 10.03.2019 | Clinical trials of Allergan’s antidepressant rapastinel fail | The three studies – RAP-MD-01, -02 and -03 – measured change over a three-week period in baseline measurements on the Montgomery-Asberg Depression Rating Scale, or MADRS, at the end of the study as their primary endpoints, according to Clin... |
| 16.01.2019 | Aptinyx shares crater as lead drug fails in PhII neuropathic pain study | Aptinyx’s approach to modulating the NMDA receptor to treat disorders of the central nervous system has hit a significant snag, as its lead experimental drug failed a mid-stage study in patients with diabetic periph... |
| 03.12.2018 | 5 Startup Trends that Shaped the Midwest in 2018
1. Marketplaces remain one of the strongest tech sectors
2. Health care gets even hotter
3. Logistics keeps on truckin’
4. Big bets on enterprise s... | 2018 is quickly drawing to its close, but the Midwest’s venture capital activity is still buzzing. Just this week, celebrity shoutout marketplace startup Cameo announced that it closed a $12.5 million round of funding led by Lightspeed Vent... |
| 29.11.2018 | 5 startup trends that shaped the Midwest in 2018 | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
2018 is quickly drawing to its close, but the Mid... |
| 29.11.2018 | 5 startup trends that shaped the Midwest in 2018 | 2018 is quickly drawing to its close, but the Midwest’s venture capital activity is still buzzing. Just this week, celebrity shoutout marketplace startup Cameo announced that it closed a $12.5 million round of funding led by Lightspeed Vent... |
| 05.10.2018 | Chicago’s Startups Continue to Lead the Nation in Returns | PitchBook revealed its 2018 Chicago VC Ecosystem report, released in conjunction with ChicagoNEXT’s Chicago Venture Summit. This report finds that Chicago continues to outpace other U.S. venture ecosystems — including the Bay Area — in medi... |
| 03.10.2018 | Chicago’s startups continue to lead the nation in returns | Today, PitchBook revealed its 2018 Chicago VC Ecosystem report, released in conjunction with ChicagoNEXT’s Chicago Venture Summit. This report finds that Chicago continues to outpace other U.S. venture ecosystems — including the Bay Area — ... |
| 03.10.2018 | Chicago’s startups continue to lead the nation in returns | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
Today, PitchBook revealed its 2018 Chicago VC Eco... |
| 24.05.2018 | Aptinyx looks to bring its NMDA pipeline to Nasdaq, filing for an $80 million IPO | A day after Aptinyx closed an option deal with Allergan for a small molecule depression drug, the biotech handed in its S-1, penciling in an $80 million raise as it looks to join the IPO queue. If they make it, they will trade u... |
| 20.02.2018 | How Illinois Universities Power the Chicago Startup Ecosystem | Ten years ago, Chicago was not a major player in the startup ecosystem. Now, it’s one of the most important cities in tech. |
| 28.12.2017 | Midwest Report: All of the Region’s Major Tech Fundings, M&As, and IPOs in December | While we’re primarily focused on Chicago's innovation economy, we also have our eyes on all of the startup and tech activity happening throughout the entire Midwest. Here are the major tech fundings, acquisitions, mergers, moves, and IPOs t... |
| 28.12.2017 | Midwest Report: All of the Region’s Major Tech Fundings, M&As, and IPOs in December | While we’re primarily focused on the Twin Cities innovation economy, we also have our eyes on all of the startup and tech activity happening throughout the entire Midwest. Here are the major tech fundings, acquisitions, mergers, moves, and ... |
| 26.12.2017 | Chicago Tech Raised $113M in December | Chicago-area tech and startup companies received at least $113 million in venture capital funding in December as the year comes to a close.
It’s a dip from November, when Chicago tech raised more than $184 million. But it’s still a strong f... |
| 18.12.2017 | Bain leads big $70M round as Aptinyx plunges deeper into NMDA work | Two years after Aptinyx spun out of Naurex in the wake of Allergan’s $560 million buyout, the biotech is much further along in the pipeline than your average fledgling. It just tacked on a hefty $70 million B round to beef up the... |
| 18.12.2017 | Bain Capital Life Sciences Leads $70M Series B for Aptinyx | Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today is announcing the completion of a $70 million Series B financing to fund advancement of its expanding c... |
| 18.12.2017 | Aptinyx Raises $70M in Series B Financing | Aptinyx, Inc., an Evanston, IL-based clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, completed a $70m Series B financing.
The round was led by Bain Capital Life Sciences wit... |
| 18.12.2017 | Bain Capital Life Sciences Leads $70M Series B for Aptinyx | Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today is announcing the completion of a $70 million Series B financing to fund advancement of its expanding c... |
| 18.12.2017 | Biopharma Startup Aptinyx Raises $70M | Local biopharmaceutical startup Aptinyx, which is working to develop therapies for neurologic diseases like Parkinson’s and post-traumatic stress disorder, raised $70 million in a Series B round, the company announced today.
The round was l... |
| 18.12.2017 | Aptinyx Raises $70M in Series B |
EVANSTON, Ill, Clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, has completed a $70 million Series B.
>> Click here for more funding data on Aptinyx
>> To exp... |
| 18.12.2017 | Term Sheet — Monday, December 18 | UBER DRAMA
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
If these allegations are proven true, it could result in regulatory sanctions, fines, and further criminal investigations. Not exact... |
| 07.06.2016 | Longitude Capital raises $525M for third fund spanning early to late stage medtech investments | The investment firm expects to invest an average of $15 million to 25 million per investment in approximately 25 companies. It raised $385 million for its second fund in 2012.
Galletti highlighted some of the technologies in which it has de... |
| 10.05.2016 | With a $65M Round, Aptinyx Gets One Step Closer Treating an Array of Neurological Disorders | People suffering from neurological disorders, such as Parkinson's and post-traumatic stress disorder, often struggle with noticeable symptoms for months, even years, before finding the treatment that can help pull them to recovery.
But the ... |
| 10.05.2016 | Aptinyx Lands $65M Series A Round |
EVANSTON, IL, Aptinyx today announced the completion of a $65 million Series A financing.
>> Click here for more funding data on Aptinyx
>> To export Aptinyx funding data to PDF and Excel, click here
Aptinyx, a biopharmac... |
| 10.05.2016 | Aptinyx Raises $65M in Series A Financing | Aptinyx Inc., an Evanston, IL-based biopharmaceutical company developing novel modulators of the N-methyl-D-aspartate (NMDA) receptor for the treatment of challenging neurological disorders, completed a $65m Series A funding.
The round was ... |
| - | Clinical trials of Allergan’s antidepressant rapastinel fail | An investment by Allergan of more than half a billion dollars appears not to have paid off.
The Dublin-based drugmaker said Wednesday that the three clinical trials of rapastinel, as an adjunctive treatment for major depressive disorder, di... |
| - | Longitude Capital raises $525M for third fund spanning early to late stage medtech investments | Longitude Capital, a life science investment firm targeting mostly mid to late stage companies with about one quarter for early stage businesses, has made its first close for Longitude Venture Partners III, raising a total of $525 million, ... |
